Brian Wiley

Brian Wiley

Auto-generated profile, based on publicly available information

Brian Wiley

Division of Oncology, Department of Medicine, Washington University School of Medicine (WUSM), St. Louis, Missouri. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DTDuc Tran
Duc Tran
JBJ. Scott. Beeler
J. Scott. Beeler
JLJie Liu
Jie Liu
BWBrian Wiley
Brian Wiley
ICIrenaeus C.C. Chan
Irenaeus C.C. Chan
KBKelly L. Bolton
Kelly L. Bolton
Purpose: Clonal hematopoiesis (CH) is thought to be the origin of myeloid neoplasms (MN). Yet, our understanding of the mechanisms driving CH progression to MN and clinical risk prediction of MN remains limited. The human proteome reflects complex interactions between genetic and epigenetic regulation of biological systems. We hypothesized that the plasma proteome might predict MN risk and inform our understanding of the mechanisms promoting MN development. Experimental Design: We jointly characterized CH and plasma proteomic profiles of 46,237 individuals in the UK Biobank at baseline study entry. During 500,036 person-years of follow-up, 115 individuals developed MN. Cox proportional hazard regression was used to test for an association between plasma protein levels and MN risk. Results: We identified 115 proteins associated with MN risk, of which 30% (N = 34) were also associated with CH. These were enriched for known regulators of the innate and adaptive immune system. Plasma proteomics improved the prediction of MN risk (AUC = 0.85; P = 5×10–9) beyond clinical factors and CH (AUC = 0.80). In an independent group (N = 381,485), we used inherited polygenic risk scores (PRS) for plasma protein levels to validate the relevance of these proteins toMNdevelopment. PRS analyses suggest that most MN-associated proteins we identified are not directly causally linked toMN risk, but rather represent downstream markers of pathways regulating the progression of CH to MN. Conclusions: These data highlight the role of immune cell regulation in the progression of CH to MN and the promise of leveraging multi-omic characterization of CH to improveMN risk stratification. See related commentary by Bhalgat and Taylor, p. 3095

1 August 2024
Verified
Other
Open access
DTDuc Tran
Duc Tran
JBJ. Scott Beeler
J. Scott Beeler
JLJie Liu
Jie Liu
BWBrian Wiley
Brian Wiley
ICIrenaeus C.C. Chan
Irenaeus C.C. Chan
KBKelly L. Bolton
Kelly L. Bolton
Association between plasma protein levels and clonal hematopoiesis (CH) stratified by VAF.

1 August 2024
Verified
Other
Open access
PDF file
DTDuc Tran
Duc Tran
JBJ. Scott Beeler
J. Scott Beeler
JLJie Liu
Jie Liu
BWBrian Wiley
Brian Wiley
ICIrenaeus C.C. Chan
Irenaeus C.C. Chan
KBKelly L. Bolton
Kelly L. Bolton
Association between plasma protein levels and blood count parameters.

1 August 2024
Verified
Other
Open access
DTDuc Tran
Duc Tran
JBJ. Scott Beeler
J. Scott Beeler
JLJie Liu
Jie Liu
BWBrian Wiley
Brian Wiley
ICIrenaeus C.C. Chan
Irenaeus C.C. Chan
KBKelly L. Bolton
Kelly L. Bolton
Significantly enriched Reactome gene sets after multiple hypothesis testing correction (pFDR <= 0.05).

1 August 2024
Verified
Other
Open access
DTDuc Tran
Duc Tran
JBJ. Scott Beeler
J. Scott Beeler
JLJie Liu
Jie Liu
BWBrian Wiley
Brian Wiley
ICIrenaeus C.C. Chan
Irenaeus C.C. Chan
KBKelly L. Bolton
Kelly L. Bolton
Two-sample Mendelian randomization analyses of the causal effect of plasma protein levels on myeloid neoplasm (MN) risk in the UKBB.

1 August 2024
Verified
Other
Open access
DTDuc Tran
Duc Tran
JBJ. Scott Beeler
J. Scott Beeler
JLJie Liu
Jie Liu
BWBrian Wiley
Brian Wiley
ICIrenaeus C.C. Chan
Irenaeus C.C. Chan
KBKelly L. Bolton
Kelly L. Bolton
Association between plasma protein levels and risk of myeloid neoplasm (MN) with and without adjustment for clonal hematopoiesis (CH).